The case for & against
Bull & Bear analysis
Endra Life Sciences (NASDAQ: NDRA) specializes in non-invasive diagnostic imaging technologies focusing on liver health. The company is advancing its flagship product, the Thermoacoustic Enhanced Ultrasound Liver System (TEIS), which aims to set a new standard for diagnosing fatty liver disease—a condition affecting a significant portion of the global population. Positioned within the healthcare sector, specifically in medical technology, Endra seeks to capitalize on the rising demand for accurate, cost-effective diagnostic tools amidst increasing incidences of liver disorders worldwide.
Bull says
- ↑Rising global liver disease prevalence underpins TEIS market opportunity
- ↑Submitted FDA de novo request; agency targets decision within 150 days
- ↑Operating expenses down 27% YoY to $2.2 M, extending cash runway
- ↑Expanded patent portfolio to 81 issued patents, reinforcing competitive moat
- ↑High institutional ownership and strong liquidity signal investor confidence
- ↑Positive analyst revisions hint at potential earnings upgrades
Bear says
- ↓2023 net loss of $10.1 M vs. $13.2 M prior year underscores persistent unprofitability
- ↓Cash runway limited into H1 2025, raising liquidity and funding concerns
- ↓FDA de novo delays risk postponing U.S. market entry beyond projected timelines
- ↓Negative profitability and earnings yield factors signal weak margin potential
- ↓Elevated leverage risk indicated by adverse debt management factor score
- ↓Intense competition from EXAS, GE, PHG and emerging GLP-1 diagnostics
Investment themes with NDRA
Clinical instruments and devices powering patient care
Stocks with highest short interest
Earnings Call · Q2 2023 · Mgmt. Guidance
Transcript signals
Bull points
- We're extremely pleased to have submitted our de novo request to the US FDA for the Thermoacoustic Enhanced Ultrasound Liver System, known as TEIS, which represents an incredibly important technology milestone for ENDRA.
- sensitivity of the TAIS FLIP system in detecting fatty liver disease was 90%, with specificity of 71%, and the negative predictive value was 91%, indicating strong test performance in a cost-constrained healthcare environment.
- We believe the submitted data with 24 subjects sufficiently supports our de novo application.